The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1208
May 9, 2005
View Complete Issue         Table of Contents 2019 
Albumin-Bound Paclitaxel (Abraxane) for Advanced Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Albumin-Bound Paclitaxel (Abraxane) for Advanced Breast Cancer
May 9, 2005 (Issue: 1208)
A new albumin-bound formulation of paclitaxel (Abraxane - American Pharmaceutical Partners) has been approved by the FDA for treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Albumin-Bound Paclitaxel (Abraxane) for Advanced Breast Cancer
Article code: 1208c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.